Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
148 hedge funds and large institutions have $1.57B invested in Avidity Biosciences in 2022 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 75 increasing their positions, 21 reducing their positions, and 18 closing their positions.
257% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 21
128% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 18
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
80% more capital invested
Capital invested by funds: $872M → $1.57B (+$696M)
17% more funds holding
Funds holding: 127 → 148 (+21)
5.3% more ownership
Funds ownership: 102.46% → 107.76% (+5.3%)
44% less call options, than puts
Call options by funds: $3.1M | Put options by funds: $5.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$49M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.7M |
| 5 |
BlackRock
New York
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$47.3M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$35.4M |
| 3 |
Walleye Capital
New York
|
-$4.42M |
| 4 |
ACM
Altium Capital Management
New York
|
-$2.45M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.71M |
RNAM Hedge Fund Activity: Q4 2022 in Review
148 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2022, worth a combined $1.57B — up 80% from $872M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new RNAM positions and 18 closed out — a net gain of 23 holders — while 75 added to existing stakes and 21 trimmed.
The largest buyer was RA Capital Management, adding an estimated $49M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $47.3M sold.
- 148 institutional investors held Avidity Biosciences (RNAM) as of Q4 2022, up from 127 in Q3 2022.
- Funds reported $1.57B of Avidity Biosciences stock for Q4 2022, up 80% quarter-over-quarter.
- 41 funds opened new Avidity Biosciences positions in Q4 2022 and 18 closed out, a net change of +23 holders.
- The largest Avidity Biosciences buyer in Q4 2022 was RA Capital Management, an estimated $49M added.
- The largest Avidity Biosciences seller in Q4 2022 was EcoR1 Capital, an estimated $47.3M sold.
Based on aggregated 13F filings for Q4 2022.